Director, Tri-I TDI
Michael Foley is the Director of the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), a newly formed partnership between Memorial Sloan Kettering , The Rockefeller University and Weill Cornell Medical College, to speed drug discovery. Foley brings 25 years of industry and academic experience to Tri-I TDI, helping to launch four companies and one academic institute and placing 12 drugs into clinical development. He was most recently the Director of the Chemical Biology Platform at the Broad Institute of MIT and Harvard. Michael was a co-founder of Infinity Pharmaceuticals and served as VP Chemistry from 2001 to 2006. He was also a co-founder of CombinatoRx and Forma Therapeutics, as well as working at Bristol-Myers Squibb and GlaxoSmithKline. He obtained his Ph.D. at Harvard, and helped establish the Harvard Institute of Chemistry and Cell Biology. In 2006, Michael joined the Broad Institute and served as director of the Therapeutics Platform. Foley received his B.S. in chemistry from St. Norbert College and his Ph.D. in chemistry from Harvard University.